Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01783145
Other study ID # SCFU-TC 1.2011
Secondary ID 38710
Status Active, not recruiting
Phase
First received
Last updated
Start date October 2012
Est. completion date January 2025

Study information

Verified date May 2024
Source University Medical Center Groningen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to develop and evaluate a shared care survivorship care plan (SCP) to follow-up patients with metastatic testicular cancer after completion of chemotherapy that resulted in complete remission.


Description:

Rationale: Since the introduction of cisplatin, metastatic testicular cancer (TC) has become a highly curable disease. Successfully treated TC patients have a small chance of a relapse. In case of a relapse, early treatment will improve outcome. This stresses the need for a frequent and stringent follow-up scheme. Although chemotherapy is a very effective treatment, a downside of this treatment has now become apparent: chemotherapy-related complications such as the increased risk for cardiovascular disease (CVD) and secondary malignancies. CVD can manifest during treatment, but also years or decades thereafter. We recently observed early development of cardiovascular risk factors in TC patients, clustered into the metabolic syndrome. Monitoring and treatment of cardiovascular risk factors during follow-up is important to lower the chance of developing CVD. Since TC survivors are discharged from follow-up after 10 years, collaboration between oncologists and general practitioners (GPs), in other words shared care, will ensure monitoring of cardiovascular risk factors and timely detection and treatment of late effects (cardiovascular risk management). Survivorship care plans for cancer survivors, GPs and oncologists facilitate care for long-term survivors. The testicular cancer survivor himself is the key person, who can be empowered to participate in follow-up programs and make lifestyle adjustments to decrease the risk of late effects and improve quality of life and life expectancy. However, data are scarce on the design of an evidence based effective follow-up schedule. For childhood cancer survivors a detailed guideline has been developed that can serve as a framework for adult cancer survivor follow-up. Objective: To examine the safety and feasibility of a shared care survivorship care plan (SCP) to follow-up patients with metastatic testicular cancer after completion of chemotherapy that resulted in complete remission. Study population: Patients that achieved a complete remission after chemotherapy for metastatic testicular cancer who are starting with follow-up or are currently in active follow-up.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 163
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with disseminated testicular cancer; - Complete remission after chemotherapy with or without adjunctive surgery and in active follow-up; - Age 18 years or older; - Started with chemotherapy after January 1st 2003; - Written informed consent. Exclusion Criteria: •Mental disability

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands University Medical Center Groningen Groningen

Sponsors (1)

Lead Sponsor Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of a shared care survivorship care plan (SCP). The aim of this study is to develop and evaluate a shared care SCP to follow-up patients with disseminated TC after completion of chemotherapy. Participants in the SCP will be patients, GPs and oncologists. The SCP will be defined according to follow-up guidelines for TC patients, with a focus on disease relapse and late effects. Monitoring of safety will be done on a continuous basis with average duration of two years per participant.
Primary Feasibility of a shared care survivorship care plan (SCP). The aim of this study is to develop and evaluate a shared care SCP to follow-up patients with disseminated TC after completion of chemotherapy. Participants in the SCP will be patients, GPs and oncologists. The SCP will be defined according to follow-up guidelines for TC patients, with a focus on disease relapse and late effects. Monitoring of feasibility will be done on a continuous basis with average duration of two years per participant.
Secondary Satisfaction with the SCP of testicular cancer survivors, GPs and oncologists. The satisfaction with the SCP of testicular cancer survivors, GPs and oncologists will be evaluated by using questionnaires. Up to two years.
Secondary Willingness to migrate from hospital care to primary care. The willingness to migrate from hospital care to primary care will be evaluated by specifying the decisions made within the SCP and by questionnaires to patients and GPs. Up to two years.
See also
  Status Clinical Trial Phase
Recruiting NCT00772694 - Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Phase 2
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Terminated NCT00531687 - Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer Phase 2
Terminated NCT00820287 - Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk N/A
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Active, not recruiting NCT03142802 - Low-Dose CT - Stage I Testicular Cancer N/A
Recruiting NCT03232541 - The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting N/A
Completed NCT03557177 - Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT02573584 - Vascular Fingerprint Validation Study
Recruiting NCT05670938 - Follow-up After Surgery for Testicular Cancer
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT02991209 - Study of Testosterone vs Placebo in Testicular Cancer Survivors Phase 2/Phase 3
Completed NCT02602041 - Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
Completed NCT02092740 - REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg N/A
Completed NCT01482741 - Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Completed NCT00183820 - Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma Phase 2